SCHEMBL58196

SCHEMBL58196

O=C=Nc1cc(C(F)(F)F)ccc1F

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.38
PDE2A O00408 3/20 0.35
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP3A4 P08684 2/20 0.34
CES2 O00748 2/20 0.34
TRPA1 O75762 2/20 0.34
MPL P40238 1/20 0.34
TMPRSS4 Q9NRS4 1/20 0.33
TDO2 P48775 1/20 0.33
GAA P10253 1/20 0.33
PARP1 P09874 1/20 0.33
PARP10 Q53GL7 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30155312 1.00 IDO1 (0.38) IDO1PDE2AMEN1TSHRKMT2A
SCHEMBL13790098 0.86 CYP3A4 (0.36) MEN1KMT2ACYP3A4TRPA1ALDH1A1
SCHEMBL2278837 0.85 PDE2A (0.39) IDO1PDE2AMEN1TSHRKMT2A
SCHEMBL1435223 0.81 MIF (0.40) IDO1PDE2AMEN1TSHRKMT2A
SCHEMBL29717723 0.81 MIF (0.40) IDO1PDE2AMEN1TSHRKMT2A
SCHEMBL12535901 0.81 CES2 (0.46) PDE2AMEN1KMT2ACYP3A4CES2
SCHEMBL31135808 0.81 CES2 (0.46) PDE2AMEN1KMT2ACYP3A4CES2
SCHEMBL58769 0.80 MEN1 (0.46) PDE2AMEN1TSHRKMT2ACYP3A4
SCHEMBL13556581 0.80 CYP3A4 (0.58) PDE2AMEN1KMT2ACYP3A4CES2
SCHEMBL30534235 0.80 MEN1 (0.46) PDE2AMEN1TSHRKMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118006233-A High-strength washable protective film, preparation method and application thereof 河源昆腾电子科技有限公司 2024-05-10 CN claimed
CN-118016995-A Non-aqueous electrolyte containing aromatic isocyanate and lithium ion battery 诺莱特电池材料(苏州)有限公司 2024-05-10 CN claimed
CN-117736482-A Micro-foaming polyimide layered film with ultralow dielectric constant 聚埃麦德(苏州)科技有限公司 2024-03-22 CN claimed
CN-116845345-A Preparation method of gel quasi-solid electrolyte, gel quasi-solid electrolyte and lithium ion battery 阜新德尔汽车部件股份有限公司 2023-10-03 CN claimed
CN-115386245-A Preparation method and application of lipophilic carbon nitride nanosheet 浙江理工大学 2022-11-25 CN claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
EP-4713378-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2026-03-25 EP disclosed
US-12551482-B2 Aurora kinase inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-02-17 US disclosed
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2025-07-10 US disclosed
EP-3500257-B1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2025-07-02 EP disclosed
EP-4556480-A1 COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS Fileclo Spolka Z Ograniczona Odpowiedzialnoscia (PL) 2025-05-21 EP disclosed
WO-2025083280-A1 SORAFENIB ANALOGS FOR USE IN THE TREATMENT OF CANCER UNIVERSITAT DE BARCELONA (ES) 2025-04-24 WO disclosed
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NodThera Limited (GB) 2025-03-11 US disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed
WO-2002044156-A2 BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2002-06-06 WO disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed
EP-0241559-B1 OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-10-30 EP disclosed
US-4983751-A Chemical intermediates SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-01-08 US disclosed
US-4818272-A NONPHYTOTOXICITY FOR CROPS HELICAL STREAMS SAGAMI CHEMICAL RESEARCH CENTER (JP) 1989-04-04 US disclosed
EP-0241559-A1 OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME SAGAMI CHEMICAL RESEARCH CENTER (JP) 1987-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NLRP3, NOD1, NLRP1 IDO1 546/4885PDE2A 2821/4885MEN1 2492/4885
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 IDO1 546/4885PDE2A 2821/4885MEN1 2492/4885
US-12551482-B2 Aurora kinase inhibitors MYC, AURKA, AURKC IDO1 3775/4885PDE2A 4031/4885MEN1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.